Medical Review

Mikhail Blagosklonny Is Enhancing Scientific Research Through Oncotarget

Mikhail Blagosklonny is a cancer and aging scientist. He is also a professor of oncology at Roswell Park Cancer Institute. Mikhail has been a committed editor-in-chief for Oncotarget, a weekly peer-reviewed journal. Over the years, the periodical has been publishing papers on oncology and other related fields. Through Mikhail’s visionary leadership, Oncotarget has published many journals from different authors. The journal has been of great importance to experts and the public as it has broadened their understanding of oncology.

Mikhail’s mission is to eliminate boundaries between different fields of biomedical science through publishing research papers on broad topics. These subjects include aging, pathology, immunology and microbiology, chromosome, autophagy and cell death. Through Oncotarget, Mikhail and other scientists strive to ensure that people are disease-free. To this end, they encourage the application of clinical science to treat different diseases. The journal has continued to stamp its authority in the field of oncology considering that it is peer reviewed.

Mikhail Blagosklonny pursued his education at First Pavlov State Medical University in St. Petersburg. He graduated with an MD in Internal Medicine. Later, he returned to the esteemed institution to complete his PhD in Experimental Medicine and Cardiology. In 2002, Mikhail joined New York Medical College as an associate professor. In 2009, he agreed to work for Ordway Research Institute as a senior scientist. Dr. Mikhail’s research has focused on oncogens and tumor suppressors, mitosis, apoptosis, signal transduction, cell cycle, and anticancer therapeutics. He is credited for coming up with the hyper function theory of aging and anti-cancer therapies known as chemotherapeutic engineering and cell cyclotherapy. The scientist formulated a hypothesis to study the possible role of TOR signaling in cancer and aging. Mikhail is a strong advocate for rapamycin, a cancer drug that prolongs the life of a cancer patient.

Learn more: http://www.nature.com/cdd/about/biographies.html

Blagosklonny is the editor-in-chief of Aging and Cell Cycle. He serves as an associate editor for the American Journal of Pathology, PLOS ONE, and Internal Journal of Cancer. Mikhail, who co-founded Oncoscience, is also affiliated with Cell Death and Differentiation, Autophagy and Cancer Biology & Therapy. He is the author of over 300 publications, including research articles, reviews and book chapters. Mikhail’s contribution in the field of oncology and cancer research has made him one of the most sought after oncology researchers in the world. Visit ResearchGate.Net to know more about Mikhail’s latest work.